Nigel Clarke, Chairman of Attomarker, discusses how the company is helping the fight against COVID-19 through its multiplex antibody tests.
Attomarker, an investee company of Milltrust’s British Innovation Fund, is an early-stage diagnostics company that has invented a new, simple to use, point-of-care blood testing device that can perform multiple tests from a single pinprick of blood in approximately five minutes. The patented Attomarker technology uses a disposable credit-card sized chip that slots into a handheld device docked to an iPhone and provides rapid testing for the healthcare professional and the consumer markets. Alongside its response to COVID-19, Attomarker is continuing its work towards developing tests for fatty liver disease (a precursor of type-2 diabetes), food allergy diagnosis and to distinguish between bacterial and viral infections.
Attomarker’s COVID-19 test utilises the same technology but the application is a through a specially designed device, the Attomarker Liscar 4.
Attomarker is currently seeking to immediately raise 7 million GBP of an expanded A round ahead of an anticipated B round of 15-20 million GBP later this year.
Attomarker was recently selected as a candidate for the Longitude Prize, an 8 million GBP award in the fight against anti-microbial resistance. Additionally, its technology is now part of an exhibition at the Science Museum in London.
See 5 min webinar summary video below.
FOR PROFESSIONAL / QUALIFIED INVESTORS ONLY / NOT FOR PUBLIC DISTRIBUTION Statements attributed to an individual represent the opinions of that individual as of the date published and may not necessarily reflect the view of Milltrust International LLP or its affiliates. Milltrust International LLP uses reasonable efforts to obtain information from third-party sources which it believes to be reliable, Milltrust International LLP makes no representation or warranty as to the accuracy, reliability or completeness of the information. This communication is strictly private and confidential and is issued by Milltrust International LLP, incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. None of the investment products mentioned herein are regulated collective investment schemes for the purposes of the UK Financial Services and Markets Act 2000. The promotion of such products and the distribution of this document are, accordingly, restricted by law. Most of the protections provided by the UK regulatory system and compensation under the UK’s Financial Services Compensation Scheme will not be available. The investments described herein are only available to investors permitted to invest in the prospectus of the fund and are not available to private investors. The nature of the fund investments carries certain risks and the Fund may utilise investment techniques which may carry additional risk. The value of investments and the income from them may fall as well as rise and is not guaranteed. Past performance is not a reliable indicator of future performance. This document contains forward-looking statements which are correct as at the date of this document. Such statements involve known and unknown risks, uncertainties and other important factors that could cause actual results, performance or projections to be materially different from future results. Any investment in the funds mentioned above should be based on the full details contained in the relevant prospectus and supplements which are available from www.milltrust.com. Notice to US investors: the shares of Milltrust International Managed Investments ICAV and Milltrust International Investments SPC have not been registered under the 1933 Securities Act or under the 1940 Act; however the company takes advantage of the 3[C]7 exemption and shares are available to 3[C](1) US qualified purchasers and those qualifying under Reg D distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York.